Transcode Therapeutics, Inc. (RNAZ): Nasdaq/NYSE listing notice — TransCode receives Nasdaq delisting notice; plans to appeal bid-price deficiency

Transcode Therapeutics, Inc.

Company received Nasdaq notice on May 6, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive days (Mar 24–May 5).
Due to multiple reverse stock splits over prior two years (cumulative ratio >=250:1), Company is ineligible for standard compliance period; must appeal by May 13, 2025.
TransCode plans to timely request a hearing before a Nasdaq Hearings Panel; delisting stayed pending hearing outcome.
No assurance the Company will ultimately regain compliance or remain listed on Nasdaq.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Transcode Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 6, 2025, TransCode Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) informing the Company that, for the 30 consecutive business day period between March 24, 2025, through May 5, 2025, the Company’s common stock had not maintained a minimum closing bid price of $1.00 per share as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Notice also indicated that the Company is not eligible for any

View on SEC.gov

Browse all listing & compliance notices →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-045598

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.